Search results for "Placebo"

showing 10 items of 704 documents

Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach.

2022

© Crown 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the per…

GENERAL-POPULATIONAgingEvidence-Based MedicinePLACEBOPatient-centeredNONSTEROIDAL ANTIINFLAMMATORY DRUGSOsteoarthritis KneeAMERICAN-COLLEGEKNEE OSTEOARTHRITISHandCYCLOOXYGENASE-2 INHIBITORSManagementEuropeDOUBLE-BLINDPatient-Centered CareHEALTH-CAREOsteoarthritisJOINT OSTEOARTHRITISHumansADVERSE EVENTSGeriatrics and GerontologyHand Management Osteoarthritis Patient-centered Treatment guidelineReferral and ConsultationTreatment guideline
researchProduct

LEVEL OF ACTIVATION AND GOAL-DIRECTED BEHAVIOUR: The effect of chlorpromazine on aggressive, achievement oriented, and affiliation oriented verbal re…

1963

The purpose was to investigate the effect of chlorpromazine on verbal response contents in sentence completion tests. 30 male subjects participated in two chlorpromazine and one placebo session. It was found that the amount of aggressive, achievement and affiliation oriented responses was significantly reduced as an effect of drug intake. The results are discussed on the basis of the theories of conflict motivation and of arousal.

General MedicineVerbal responsePlaceboSentence completion testsArousalDevelopmental psychologyArts and Humanities (miscellaneous)Developmental and Educational PsychologymedicineSession (computer science)Drug intoxicationChlorpromazinePsychologyGeneral Psychologymedicine.drugClinical psychologyScandinavian Journal of Psychology
researchProduct

Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre tri…

2012

Objective  Previous trials have shown little benefit for preventing preterm birth in twin pregnancies using 90–200 mg of daily vaginal natural progesterone. Higher doses have not been tested. Our aim was to determine the efficacy and safety of two different daily doses of vaginal natural progesterone (200 and 400 mg), compared with placebo, for preventing preterm birth in unselected twin pregnancies. Design  Randomised controlled double-blind multicentre trial (1:1:1). Setting  The study was carried out in five university centres from Valencia, Murcia and Alicante (Spain). Population  Women with dichorionic diamniotic twin pregnancies. Methods  The women self-inserted two vaginal pessaries …

Gynecologymedicine.medical_specialtyPregnancyObstetricsbusiness.industryBirth weightObstetrics and GynecologyPlacebomedicine.diseaselaw.inventionRandomized controlled trialPremature birthlawmedicineGestationAdverse effectbusinessTwin PregnancyBJOG: An International Journal of Obstetrics & Gynaecology
researchProduct

P29.02: Assessment of placental vascularization by three-dimensional power Doppler to evaluate effect of mifepristone vs. placebo in early pregnancy

2007

Gynecologymedicine.medical_specialtyRadiological and Ultrasound Technologybiologybusiness.industryObstetricsObstetrics and GynecologyEarly pregnancy factorGeneral MedicineMifepristonePlaceboPower dopplerReproductive Medicinebiology.proteinMedicineRadiology Nuclear Medicine and imagingbusinessPlacental vascularizationmedicine.drugUltrasound in Obstetrics and Gynecology
researchProduct

Botulinum Toxin Injection Plus Topical Diltiazem for Chronic Anal Fissure: A Randomized Double-Blind Clinical Trial and Long-term Outcome.

2021

BACKGROUND: Chemical sphincterotomy avoids the risk of permanent incontinence in the treatment of chronic anal fissure, but it does not reach the efficacy of surgery and recurrence is high. Drug combination has been proposed to overcome these drawbacks.; OBJECTIVE: This study aimed to compare the clinical, morphological, and functional effects of combined therapy with botulinum toxin injection and topical diltiazem in chronic anal fissure and to assess the long-term outcome after healing.; DESIGN: This is a randomized, controlled, double-blind, 2-arm, parallel-group trial with a long-term follow-up.; SETTINGS: This study was conducted at a tertiary care center.; PATIENTS: A total of 70 cons…

Gynecologymedicine.medical_specialtybusiness.industryGastroenterologyChronic anal fissureBotulinum toxin injectionGeneral MedicineTopical diltiazemPlaceboSymptomatic reliefClinical trialDouble blindFissure recurrenceBotulinum toxinmedicineCombined therapyDiltiazembusinessChronic anal fissuremedicine.drug
researchProduct

Multicentre study of gestrinone in cyclical breast pain FRIEDOLF PETERS

1992

Although the aetiology of cyclical mastalgia is poorly understood, the consistent finding of an increased prolactin stimulation response probably due to oestrogen dominance has led to the use of treatment with prolactin-lowering drugs and antioestrogens. The efficacy and safety in cyclical mastalgia of gestrinone, which has androgenic, anti-oestrogenic, and antiprogestagenic properties, were investigated in a multicentre study. In a double-blind randomisation procedure, 72 patients were allocated placebo and 73 treatment with gestrinone (2.5 mg twice a week) for 3 months. The patients recorded the severity of breast pain on a visual analogue scale before and during treatment and scored othe…

Gynecologymedicine.medical_specialtybusiness.industryVisual analogue scaleBreast painGeneral MedicineGestrinonePlaceboGastroenterologyProlactinlaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessmedicinemedicine.symptombusinessMastodyniamedicine.drugThe Lancet
researchProduct

Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuva…

2021

167 Background: NIVO is the first adjuvant therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus PBO in resected EC/GEJC following neoadjuvant chemoradiotherapy as demonstrated by CheckMate 577. NIVO was well tolerated with an acceptable safety profile. This analysis provides additional information on the exploratory HRQoL endpoints in this clinical trial. Methods: The effect of NIVO versus PBO on HRQoL, including general and disease-related symptoms, functioning, disease burden, and overall QoL, was assessed using FACT-E and EQ-5D-3L patient-reported outcome (PRO) questionnaires administered at baseline (BL), every 4 wee…

Health related quality of lifeCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerGastroesophageal JunctionPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicinemedicineAdjuvant therapyNivolumabbusinessAdjuvantJournal of Clinical Oncology
researchProduct

Reduced inotropic support after aprotinin therapy during pediatric cardiac operations

1999

Several reports indicate that aprotinin treatment before and during cardiopulmonary bypass (CPB) might have a protective effect on the myocardium. We evaluated the hemodynamic effects of perioperative aprotinin treatment.We conducted a randomized, double-blind, placebo-controlled trial in 34 infants (mean age, 2.5 years) who had cardiac operations. Half of the patients received high-dose aprotinin therapy. There were no significant differences between the aprotinin and placebo groups with respect to age, weight, sex, aortic cross-clamp time, and CPB time. The following data were recorded at arrival in the intensive care unit 6, 12, 24, and 48 hours after termination of CPB: heart rate, bloo…

Heart Defects CongenitalMalePulmonary and Respiratory MedicineAdolescentPhosphodiesterase InhibitorsHemodynamicsPlaceboHemostaticslaw.inventionAprotininDouble-Blind MethodlawHeart rateCardiopulmonary bypassHumansMedicineEnoximoneAprotininChildEnoximoneCardiopulmonary Bypassbusiness.industryHemodynamicsInfant NewbornInfantFurosemideBlood pressureChild PreschoolAnesthesiaFemaleSurgeryCardiology and Cardiovascular Medicinebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Annals of Thoracic Surgery
researchProduct

Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions

2015

Summary What is known and objective Hyponatraemia, the most common electrolyte imbalance occurring in hospitalized subjects, is usually classified as hypovolaemic, euvolaemic or hypervolaemic. Hyponatraemia is a predictor of death among subjects with chronic heart failure and cirrhosis. The inappropriate secretion of the antidiuretic hormone (AVP) seems to be of pivotal importance in the decline of serum sodium concentration in these clinical conditions. The objective of this review was to summarize recent progress in management of hyponatraemia in SIADH, cirrhosis and heart failure. Methods Literature searches were conducted on the topics of hyponatraemia and vasopressin receptor antagonis…

Heart FailureLiver CirrhosisPharmacologyAquapheresismedicine.medical_specialtyCirrhosisbusiness.industrymedicine.medical_treatmentSodiumVolume overloadmedicine.diseasePlaceboHypertonic salineInappropriate ADH SyndromeAnesthesiaHeart failuremedicineHumansPharmacology (medical)DecompensationbusinessIntensive care medicineAntidiuretic Hormone Receptor AntagonistsHyponatremiaAntidiureticJournal of Clinical Pharmacy and Therapeutics
researchProduct

Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design

2022

Abstract Purpose Clinical practice forces the necessity to conduct a clinical trial concerning the group of outpatients with chronically advanced heart failure in III or IV NYHA functional class, frequently requiring hospitalizations due to HF exacerbation, and often left without any additional therapeutic option. The current trial aims to determine the efficacy and safety of repeated levosimendan infusions in the group of severe outpatients with reduced ejection fraction (HFrEF). Material and methods LEIA-HF (LEvosimendan In Ambulatory Heart Failure Patients) is a multicentre, randomized, double-blind, placebo-controlled, phase 4 clinical trial to determine whether the repetitive use of le…

Heart Failuremedicine.medical_specialtyCardiotonic AgentsEjection fractionExacerbationbusiness.industryStroke VolumeGeneral MedicineLevosimendanPlacebomedicine.diseaseClinical trialTreatment OutcomeDouble-Blind MethodHeart failureEmergency medicineAmbulatoryClinical endpointmedicineHumansbusinessSimendanmedicine.drugAdvances in Medical Sciences
researchProduct